2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension

{"title":"2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension","authors":"","doi":"10.1159/000076263","DOIUrl":null,"url":null,"abstract":"Accessible online at: www.karger.com/hed S.E.K. is a member of the Council of the European Society of Hypertension and of the Writing Group of the 2003 European Society of Hypertension-European Society of Cardiology Guidelines. Hypertension, hypercholesterolemia and smoking are the most important risk factors for cardiovascular disease and death. For the first time, the European sister organizations European Society of Hypertension (ESH) and European Society of Cardiology (ESC) have come out with joint guidelines regarding the detection and treatment of hypertension – printed in this special issue of Heart Drug. It is realized that cardiologists play a key role more than ever in the care of hypertensive patients and an increasingly important role as educators in this field. The Guidelines Paper was developed by experts in the cardiovascular field and key opinion leaders from most countries in Europe. The guidelines are based on the 1999 International Society of Hypertension/World Health Organization Guidelines and they are endorsed by the International Society of Hypertension. It is a thorough educational document with more than 300 quotations of important publications. The new guidelines integrate detection and treatment of other important risk factors, including diabetes. A new issue in the risk assessment of hypertensive patients and for the first time included in the guidelines is the detection of target organ damage like left ventricular hypertrophy, arterial plaque, microalbuminuria or slightly elevated serum creatinine. With a 10-year risk of cardiovascular disease of 20% or more, drug treatment for hypertension is always warranted, and a statin and acetylsalicylic acid would usually be indicated. In contrast to the 2003 American Guidelines (JNC-7), in these guidelines, a number of different drugs are considered evidence-based first-line treatment, and combination treatment is strongly recommended to reach blood pressure targets. A shortened ‘Practical Guidelines’ has been developed and will be translated into various European languages. It is expected that the 2003 ESH-ESC Guidelines will soon be implemented in all countries within the area of the European Union. Hopefully, these clinically oriented guidelines will provide the basis for improved hypertension care and control in Europe!","PeriodicalId":87985,"journal":{"name":"Heartdrug : excellence in cardiovascular trials","volume":"4 1","pages":"6 - 51"},"PeriodicalIF":0.0000,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000076263","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heartdrug : excellence in cardiovascular trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000076263","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Accessible online at: www.karger.com/hed S.E.K. is a member of the Council of the European Society of Hypertension and of the Writing Group of the 2003 European Society of Hypertension-European Society of Cardiology Guidelines. Hypertension, hypercholesterolemia and smoking are the most important risk factors for cardiovascular disease and death. For the first time, the European sister organizations European Society of Hypertension (ESH) and European Society of Cardiology (ESC) have come out with joint guidelines regarding the detection and treatment of hypertension – printed in this special issue of Heart Drug. It is realized that cardiologists play a key role more than ever in the care of hypertensive patients and an increasingly important role as educators in this field. The Guidelines Paper was developed by experts in the cardiovascular field and key opinion leaders from most countries in Europe. The guidelines are based on the 1999 International Society of Hypertension/World Health Organization Guidelines and they are endorsed by the International Society of Hypertension. It is a thorough educational document with more than 300 quotations of important publications. The new guidelines integrate detection and treatment of other important risk factors, including diabetes. A new issue in the risk assessment of hypertensive patients and for the first time included in the guidelines is the detection of target organ damage like left ventricular hypertrophy, arterial plaque, microalbuminuria or slightly elevated serum creatinine. With a 10-year risk of cardiovascular disease of 20% or more, drug treatment for hypertension is always warranted, and a statin and acetylsalicylic acid would usually be indicated. In contrast to the 2003 American Guidelines (JNC-7), in these guidelines, a number of different drugs are considered evidence-based first-line treatment, and combination treatment is strongly recommended to reach blood pressure targets. A shortened ‘Practical Guidelines’ has been developed and will be translated into various European languages. It is expected that the 2003 ESH-ESC Guidelines will soon be implemented in all countries within the area of the European Union. Hopefully, these clinically oriented guidelines will provide the basis for improved hypertension care and control in Europe!
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2003年欧洲高血压学会-欧洲心脏病学会动脉高血压管理指南
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Safety of Bone Marrow Stem Cell Mobilization Induced by Granulocyte-Colony Stimulating Factor: 30 Days’ Blinded Clinical Results from the Stem Cells in Myocardial Infarction (STEMMI) Trial Rationale and Design of the OACIS-LIPID Study That Evaluates Early Use of Pravastatin in Acute Myocardial Infarction Hyperglycemia after Acute Ischemic Stroke: Prediction, Significance and Immediate Control with Insulin-Potassium-Saline-Magnesium Infusions Nicorandil – Review of Pharmacological Properties and Clinical Applications Can Statins Be Considered as a Tertiary Level Agent in Patients with Failure of Conventional Oral Hypoglycemic Agents?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1